Journal Name: Signal Transduction and Targeted Therapy
Journal Type: Q1
ISSN: 20593635, 20959907
Country: United Kingdom
Subject Area and Category: Biochemistry, Genetics and Molecular Biology Cancer Research Genetics
Publisher: Springer Nature
Research Ranking: 82
Publication Type: Journals
H-Index: 161
Coverage: 2016-2025
Editors-in-Chief: Carlo M. Croce , Kang Zhang , Yuquan Wei
Research Impact Score: 10.1
Impact Factor: 40.8
SCIMAGO SJR: 12.135
APC Cost: $3790
Homepage: https://www.nature.com/sigtrans/
Submission Link: https://www.nature.com/sigtrans/
Contact Email: ramiaq@ekmd.huji.ac.il
Address: State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Overview
In the rapidly advancing field of biomedical science, signal transduction and targeted therapy have emerged as crucial components in understanding and treating a variety of diseases, especially cancer. These concepts represent a shift from traditional, broad-spectrum treatments to more personalized and precise medical interventions. This article provides a comprehensive overview of how signal transduction works and how it is being leveraged for targeted therapies.
What Is Signal Transduction?
Signal transduction is the biological process by which cells respond to external stimuli and convert them into internal signals, resulting in specific cellular responses. This communication typically starts when a signaling molecule (like a hormone or growth factor) binds to a receptor on the cell surface. This triggers a cascade of molecular events inside the cell, involving proteins such as kinases, second messengers like calcium ions, and transcription factors that eventually alter gene expression or cellular behavior.
These pathways are tightly regulated in healthy cells. However, abnormalities in signal transduction are often linked to diseases such as cancer, diabetes, and autoimmune disorders. For example, mutations that cause constant activation of signaling proteins can lead to uncontrolled cell growth and cancer.
The Role of Signal Transduction in Disease
In cancer and other chronic diseases, signal transduction pathways often become dysregulated. Genes such as EGFR, HER2, and BRAF—which encode proteins involved in signaling—can be mutated or overexpressed, leading to persistent growth signals even in the absence of external cues. This contributes to tumor development, metastasis, and resistance to conventional treatments.
Understanding these faulty signaling mechanisms has opened new avenues for disease diagnosis, prognosis, and, most importantly, therapy.
What Is Targeted Therapy?
Targeted therapy is a form of treatment that specifically targets the molecular changes responsible for disease. Unlike traditional chemotherapy, which affects both healthy and cancerous cells, targeted therapies aim to block the specific molecules or pathways that are overactive or mutated in diseased cells.
Drugs like imatinib (for chronic myeloid leukemia), trastuzumab (for HER2-positive breast cancer), and vemurafenib (for BRAF-mutant melanoma) are successful examples of targeted therapies. These treatments work by binding to abnormal proteins and inhibiting their function, thereby halting disease progression with fewer side effects.
The Future of Targeted Therapy
With the growing integration of genomics, proteomics, and personalized medicine, targeted therapies are becoming increasingly sophisticated. Researchers are developing combination therapies that target multiple pathways simultaneously, as well as immunotherapies that work in tandem with signaling inhibitors.
Moreover, the study of signal transduction continues to uncover novel drug targets, offering hope for more effective and tailored treatments.
About
Signal transduction and targeted therapy are revolutionizing the field of cancer treatment and other chronic diseases by offering a more precise and effective approach. Unlike traditional therapies, which often affect both healthy and diseased cells, targeted therapies interfere with specific molecular targets involved in disease progression. At the heart of these therapies lies the complex process of signal transduction—the method by which cells respond to external signals.
What is Signal Transduction?
Signal transduction is a series of biochemical processes through which a cell converts an external signal into a functional change. This process begins when signaling molecules, such as hormones or growth factors, bind to specific receptors on the cell surface. These receptors then activate a cascade of intracellular signals, often involving kinases, enzymes, or secondary messengers, which ultimately lead to cellular responses like growth, division, differentiation, or apoptosis.
Aberrations in signal transduction pathways can lead to uncontrolled cell growth and cancer. For instance, mutations in genes encoding growth factor receptors or downstream signaling molecules can cause constant activation of these pathways, even in the absence of external signals.
Targeted Therapy: Precision Treatment
Targeted therapy aims to block these abnormal signaling pathways that drive disease. Unlike chemotherapy, which affects rapidly dividing cells indiscriminately, targeted therapy is designed to interfere with specific molecules necessary for tumor growth and survival.
Some common targets include:
-
EGFR (Epidermal Growth Factor Receptor): Overexpressed in several cancers, including lung and colorectal cancer.
-
HER2 (Human Epidermal Growth Factor Receptor 2): A key target in breast cancer.
-
BRAF and MEK proteins: Often mutated in melanoma.
-
VEGF (Vascular Endothelial Growth Factor): Involved in the formation of new blood vessels (angiogenesis) that support tumor growth.
By inhibiting these pathways, targeted therapies can slow or stop disease progression with fewer side effects compared to conventional treatments.
Types of Targeted Therapies
-
Monoclonal Antibodies – Engineered proteins that bind to specific antigens on the surface of cancer cells, blocking growth signals or marking cells for immune destruction.
-
Small Molecule Inhibitors – These penetrate the cell and block enzymes or proteins involved in signal transduction, such as tyrosine kinase inhibitors (TKIs).
-
Hormone Therapies – Target hormone-sensitive cancers like breast and prostate cancer by interfering with hormone signaling pathways.
Benefits and Limitations
Targeted therapy has shown great promise in improving survival rates and quality of life. However, not all patients respond equally, and resistance can develop over time. Therefore, biomarker testing and personalized medicine are crucial for selecting the right therapy for each individual.
Scope
Signal transduction and targeted therapy are rapidly evolving fields in biomedical research and clinical medicine, with significant implications for disease treatment, especially in oncology. These approaches focus on understanding and intervening in the cellular communication pathways that regulate growth, survival, and differentiation, offering new hope for more precise and effective treatments.
What is Signal Transduction?
Signal transduction refers to the process by which cells respond to external stimuli through a series of molecular events, typically involving protein interactions and phosphorylation cascades. These pathways transmit signals from the cell surface to the nucleus, resulting in changes in gene expression and cellular behavior. Dysregulation of these pathways is a hallmark of many diseases, including cancer, autoimmune disorders, and neurodegenerative conditions.
Common signal transduction pathways include the MAPK/ERK, PI3K/AKT, and JAK/STAT pathways. Aberrant activation of these signaling networks can lead to uncontrolled cell proliferation and survival, making them critical targets for therapeutic intervention.
Rise of Targeted Therapy in Modern Medicine
Targeted therapy is a form of precision medicine that specifically inhibits molecules involved in signal transduction pathways driving disease progression. Unlike traditional chemotherapy, which affects both healthy and cancerous cells, targeted therapies are designed to interfere with specific molecular targets, reducing side effects and improving outcomes.
For example, tyrosine kinase inhibitors (TKIs) like imatinib have revolutionized the treatment of chronic myeloid leukemia by blocking the BCR-ABL fusion protein. Similarly, HER2 inhibitors such as trastuzumab are effective in HER2-positive breast cancer by targeting the HER2 receptor involved in cell signaling.
Expanding Applications Beyond Cancer
While targeted therapy is most commonly associated with cancer treatment, its scope is expanding. Researchers are exploring targeted approaches for inflammatory diseases, cardiovascular conditions, and even rare genetic disorders. Drugs that inhibit Janus kinases (JAKs) have shown promise in treating rheumatoid arthritis and other autoimmune diseases by modulating cytokine signaling.
Furthermore, combining targeted therapies with immunotherapies, such as checkpoint inhibitors, is opening new avenues in cancer treatment, enhancing the immune system’s ability to recognize and destroy tumor cells.
Challenges and Future Directions
Despite the promise, challenges remain in signal transduction and targeted therapy. Drug resistance, tumor heterogeneity, and the complexity of signaling networks can limit long-term efficacy. However, advancements in genomics, proteomics, and bioinformatics are enabling better identification of therapeutic targets and biomarkers, allowing for more personalized treatment strategies.
Emerging technologies like CRISPR gene editing, nanotechnology, and AI-driven drug discovery are also playing a crucial role in accelerating the development of next-generation targeted therapies.